Document is current

Any future updates will be listed below

Cost-Effectiveness of Brentuximab Vedotin Versus Physician’s Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada

Crossref DOI link: https://doi.org/10.1007/s12325-023-02470-9

Published Online: 2023-03-15

Published Print: 2023-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark